Transfection of primary tumor cells and tumor cell lines with plasmid DNA/lipid complexes

Alison T Stopeck, Evan M Hersh, Jacqueline L. Brailey, Paul R. Clark, Jon Norman, Suezanne E. Parker

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Cancer vaccines that utilize genetically modified tumor cells require gene transfer methods capable of producing immunostimulatory doses of transgenes from fresh or short-term cultures of human tumor cells. Our studies optimize in vitro transfection of primary tumor cells using cationic lipids and a plasmid encoding the gene for human interleukin-2 (IL-2). Established tumor cell lines produced 10- to 100-fold more IL-2 than did fresh or short-term tumor cultures as measured by enzyme-linked immunoabsorbent analysis. Importantly, transfection of primary tumor cells produced immunostimulatory levels of IL-2 as determined by increased thymidine incorporation by autologous peripheral blood mononuclear cells and lymphokine-activated killer cell activity. IL-2 secretion by tumor cells persisted for at least 30 days post-transfection and was unaffected by freeze thawing or irradiation to 8000 rads. Multiple solid tumor types were successfully transfected, but normal blood mononuclear cells and leukemic blasts were resistant to transfection. Enzyme-linked immunoabsorbent analysis of the amount of IL-2 secreted into the medium by transfected tumor cells correlated with the percentage of tumor cells expressing intracellular IL-2 as measured by flow cytometry. Plasmids utilizing a cytomegalovirus promoter yielded superior transfection efficiencies compared with plasmids containing a Rous sarcoma virus promoter. These results suggest that a clinical vaccine trial using autologous tumor cells genetically modified to secrete IL-2 is feasible in patients with solid tumors.

Original languageEnglish (US)
Pages (from-to)119-126
Number of pages8
JournalCancer Gene Therapy
Volume5
Issue number2
StatePublished - 1998

Fingerprint

Tumor Cell Line
Transfection
Plasmids
Lipids
Interleukin-2
DNA
Neoplasms
Blood Cells
Lymphokine-Activated Killer Cells
Rous sarcoma virus
Cancer Vaccines
Enzymes
Cytomegalovirus
Transgenes
Thymidine
Genes
Flow Cytometry
Vaccines
Clinical Trials

Keywords

  • Cationic lipids
  • Gene transfer
  • Gene-modified tumor cells
  • Transfection

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Transfection of primary tumor cells and tumor cell lines with plasmid DNA/lipid complexes. / Stopeck, Alison T; Hersh, Evan M; Brailey, Jacqueline L.; Clark, Paul R.; Norman, Jon; Parker, Suezanne E.

In: Cancer Gene Therapy, Vol. 5, No. 2, 1998, p. 119-126.

Research output: Contribution to journalArticle

Stopeck, AT, Hersh, EM, Brailey, JL, Clark, PR, Norman, J & Parker, SE 1998, 'Transfection of primary tumor cells and tumor cell lines with plasmid DNA/lipid complexes', Cancer Gene Therapy, vol. 5, no. 2, pp. 119-126.
Stopeck, Alison T ; Hersh, Evan M ; Brailey, Jacqueline L. ; Clark, Paul R. ; Norman, Jon ; Parker, Suezanne E. / Transfection of primary tumor cells and tumor cell lines with plasmid DNA/lipid complexes. In: Cancer Gene Therapy. 1998 ; Vol. 5, No. 2. pp. 119-126.
@article{3db67168c1154802b5e66735cc5da152,
title = "Transfection of primary tumor cells and tumor cell lines with plasmid DNA/lipid complexes",
abstract = "Cancer vaccines that utilize genetically modified tumor cells require gene transfer methods capable of producing immunostimulatory doses of transgenes from fresh or short-term cultures of human tumor cells. Our studies optimize in vitro transfection of primary tumor cells using cationic lipids and a plasmid encoding the gene for human interleukin-2 (IL-2). Established tumor cell lines produced 10- to 100-fold more IL-2 than did fresh or short-term tumor cultures as measured by enzyme-linked immunoabsorbent analysis. Importantly, transfection of primary tumor cells produced immunostimulatory levels of IL-2 as determined by increased thymidine incorporation by autologous peripheral blood mononuclear cells and lymphokine-activated killer cell activity. IL-2 secretion by tumor cells persisted for at least 30 days post-transfection and was unaffected by freeze thawing or irradiation to 8000 rads. Multiple solid tumor types were successfully transfected, but normal blood mononuclear cells and leukemic blasts were resistant to transfection. Enzyme-linked immunoabsorbent analysis of the amount of IL-2 secreted into the medium by transfected tumor cells correlated with the percentage of tumor cells expressing intracellular IL-2 as measured by flow cytometry. Plasmids utilizing a cytomegalovirus promoter yielded superior transfection efficiencies compared with plasmids containing a Rous sarcoma virus promoter. These results suggest that a clinical vaccine trial using autologous tumor cells genetically modified to secrete IL-2 is feasible in patients with solid tumors.",
keywords = "Cationic lipids, Gene transfer, Gene-modified tumor cells, Transfection",
author = "Stopeck, {Alison T} and Hersh, {Evan M} and Brailey, {Jacqueline L.} and Clark, {Paul R.} and Jon Norman and Parker, {Suezanne E.}",
year = "1998",
language = "English (US)",
volume = "5",
pages = "119--126",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Transfection of primary tumor cells and tumor cell lines with plasmid DNA/lipid complexes

AU - Stopeck, Alison T

AU - Hersh, Evan M

AU - Brailey, Jacqueline L.

AU - Clark, Paul R.

AU - Norman, Jon

AU - Parker, Suezanne E.

PY - 1998

Y1 - 1998

N2 - Cancer vaccines that utilize genetically modified tumor cells require gene transfer methods capable of producing immunostimulatory doses of transgenes from fresh or short-term cultures of human tumor cells. Our studies optimize in vitro transfection of primary tumor cells using cationic lipids and a plasmid encoding the gene for human interleukin-2 (IL-2). Established tumor cell lines produced 10- to 100-fold more IL-2 than did fresh or short-term tumor cultures as measured by enzyme-linked immunoabsorbent analysis. Importantly, transfection of primary tumor cells produced immunostimulatory levels of IL-2 as determined by increased thymidine incorporation by autologous peripheral blood mononuclear cells and lymphokine-activated killer cell activity. IL-2 secretion by tumor cells persisted for at least 30 days post-transfection and was unaffected by freeze thawing or irradiation to 8000 rads. Multiple solid tumor types were successfully transfected, but normal blood mononuclear cells and leukemic blasts were resistant to transfection. Enzyme-linked immunoabsorbent analysis of the amount of IL-2 secreted into the medium by transfected tumor cells correlated with the percentage of tumor cells expressing intracellular IL-2 as measured by flow cytometry. Plasmids utilizing a cytomegalovirus promoter yielded superior transfection efficiencies compared with plasmids containing a Rous sarcoma virus promoter. These results suggest that a clinical vaccine trial using autologous tumor cells genetically modified to secrete IL-2 is feasible in patients with solid tumors.

AB - Cancer vaccines that utilize genetically modified tumor cells require gene transfer methods capable of producing immunostimulatory doses of transgenes from fresh or short-term cultures of human tumor cells. Our studies optimize in vitro transfection of primary tumor cells using cationic lipids and a plasmid encoding the gene for human interleukin-2 (IL-2). Established tumor cell lines produced 10- to 100-fold more IL-2 than did fresh or short-term tumor cultures as measured by enzyme-linked immunoabsorbent analysis. Importantly, transfection of primary tumor cells produced immunostimulatory levels of IL-2 as determined by increased thymidine incorporation by autologous peripheral blood mononuclear cells and lymphokine-activated killer cell activity. IL-2 secretion by tumor cells persisted for at least 30 days post-transfection and was unaffected by freeze thawing or irradiation to 8000 rads. Multiple solid tumor types were successfully transfected, but normal blood mononuclear cells and leukemic blasts were resistant to transfection. Enzyme-linked immunoabsorbent analysis of the amount of IL-2 secreted into the medium by transfected tumor cells correlated with the percentage of tumor cells expressing intracellular IL-2 as measured by flow cytometry. Plasmids utilizing a cytomegalovirus promoter yielded superior transfection efficiencies compared with plasmids containing a Rous sarcoma virus promoter. These results suggest that a clinical vaccine trial using autologous tumor cells genetically modified to secrete IL-2 is feasible in patients with solid tumors.

KW - Cationic lipids

KW - Gene transfer

KW - Gene-modified tumor cells

KW - Transfection

UR - http://www.scopus.com/inward/record.url?scp=0032017880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032017880&partnerID=8YFLogxK

M3 - Article

C2 - 9570303

AN - SCOPUS:0032017880

VL - 5

SP - 119

EP - 126

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 2

ER -